Gossamer Bio Faces Nasdaq Delisting Notice After Failing to Meet Minimum Bid Price Requirement

Gossamer Bio, Inc. has been formally notified by The Nasdaq Stock Market that it is not in compliance with a critical continued listing standard, triggering a potential delisting. The specific deficiency cited is the company's failure to maintain a minimum bid price of $1.00 per share for its common stock over a consecutive 30-day trading period. This notice is a significant regulatory red flag, placing the biopharmaceutical firm under immediate pressure to rectify its stock price or face removal from the exchange.

The filing of the Form 8-K on April 9, 2026, confirms the company's receipt of the Nasdaq notification. This development follows a period of trading where Gossamer Bio's share price remained below the $1.00 threshold. The notice initiates a standard compliance period, typically 180 calendar days, during which the company must demonstrate a closing bid price of at least $1.00 for a minimum of 10 consecutive business days to regain compliance. Failure to meet this requirement could lead to the delisting of its securities.

For Gossamer Bio, this situation creates substantial operational and financial uncertainty. A delisting would severely impact the company's visibility to investors, reduce liquidity for its shareholders, and complicate future capital-raising efforts. The company is now compelled to explore strategic options, which may include a reverse stock split, to mechanically boost its share price and satisfy Nasdaq's listing rules. The outcome of this compliance period will be a critical test of market confidence and corporate strategy for the clinical-stage biotech.